Truist Securities Maintains Hold on Immunovant, Raises Price Target to $22

Benzinga · 3d ago
Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $16 to $22.